{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:58Z","timestamp":1790011618550,"version":"4.0.1"},"reference-count":109,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Positron emission tomography (PET) and single photon emission tomography (SPECT) of molecular drug targets (neuroreceptors and transporters) provide essential information for therapeutic drug monitoring\u2013guided antipsychotic drug therapy. The optimal therapeutic windows for D<jats:sub>2<\/jats:sub> antagonists and partial agonists, as well as their proposed target ranges, are discussed based on an up-to-date literature search.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This part I of II presents an overview of molecular neuroimaging studies in humans and primates involving the target engagement of amisulpride, haloperidol, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, cariprazine, and ziprasidone. The systemic review particularly focused on dopamine D<jats:sub>2<\/jats:sub>-like and 5-HT<jats:sub>2A<\/jats:sub> receptors. Target concentration ranges were estimated based on receptor occupancy ranges that relate to clinical effects or side effects (ie, extrapyramidal side effects). In addition, findings for other relevant receptor systems were included to further enrich the discussion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The reported reference ranges for aripiprazole and clozapine align closely with findings from PET studies. Conversely, for haloperidol, risperidone, and olanzapine, the PET studies indicate that a lowering of the previously published upper limits would be necessary to decrease the risk of extrapyramidal side effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Molecular neuroimaging studies serve as a strong tool for defining target ranges for antipsychotic drug treatment and directing therapeutic drug monitoring.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001131","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T13:06:22Z","timestamp":1701263182000},"page":"16-32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-0189","authenticated-orcid":false,"given":"Xenia M.","family":"Hart","sequence":"first","affiliation":[{"name":"Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"},{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Spangemacher","sequence":"additional","affiliation":[{"name":"Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"},{"name":"Central Institute of Mental Health, Department of Psychiatry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[{"name":"Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"R2-20250603","first-page":"109","article-title":"Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride","volume":"44","author":"Gr\u00fcnder","year":"2003","journal-title":"J Nucl Med"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"832209","DOI":"10.3389\/fpsyt.2022.832209","article-title":"Molecular imaging of dopamine partial agonists in humans: implications for clinical practice","volume":"13","author":"Hart","year":"2022","journal-title":"Front Psychiatry"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0031-1286282","article-title":"Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging","volume":"44","author":"Gr\u00fcnder","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D\u2082 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02244811","article-title":"Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol","volume":"106","author":"Nordstr\u00f6m","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002139900333","article-title":"Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels","volume":"149","author":"Fitzgerald","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0b013e31818ba2f6","article-title":"Striatal and extrastriatal D2\/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2\/D3-receptor occupancy of ziprasidone)","volume":"28","author":"Vernaleken","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00406-011-0269-4","article-title":"Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients","volume":"262","author":"Schmitt","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pscychresns.2011.02.004","article-title":"The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study","volume":"201","author":"Corripio","year":"2012","journal-title":"Psychiatry Res"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11095-012-0906-2","article-title":"Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study","volume":"30","author":"Lim","year":"2013","journal-title":"Pharm Res"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00589893","article-title":"Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels","volume":"99","author":"Baron","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/npp.2008.116","article-title":"D2-Receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-Raclopride PET study in cats","volume":"34","author":"Ginovart","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/JCP.0000000000000065","article-title":"Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications","volume":"34","author":"Uchida","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1073\/pnas.0409766102","article-title":"Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis","volume":"102","author":"Seeman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"Breakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J Neurosci"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02251280","article-title":"5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone","volume":"110","author":"Nyberg","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"Pl103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S1461145710001148","article-title":"Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine","volume":"14","author":"Kodaka","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1177\/0269881107083810","article-title":"Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients","volume":"22","author":"Catafau","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R29-20250603","first-page":"473","article-title":"Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications","volume":"175","author":"Frankle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2967\/jnumed.110.081885","article-title":"Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812","volume":"52","author":"Catafau","year":"2011","journal-title":"J Nucl Med"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jagp.2013.01.045","article-title":"Therapeutic window for striatal dopamine D2\/3 receptor occupancy in older patients with schizophrenia: a pilot PET study","author":"Uchida","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamapsychiatry.2015.0891","article-title":"Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2\/3 receptor occupancy study","volume":"72","author":"Graff-Guerrero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuroimage.2011.07.001","article-title":"Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone","volume":"59","author":"Talbot","year":"2012","journal-title":"Neuroimage"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","article-title":"A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone","volume":"163","author":"Remington","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4088\/JCP.v69n0811","article-title":"Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia","volume":"69","author":"Uchida","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(96)00218-7","article-title":"A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects","volume":"16","author":"Nyberg","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","article-title":"D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00406-009-0082-5","article-title":"Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia","volume":"260","author":"Arakawa","year":"2010","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euroneuro.2006.07.001","article-title":"Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine","volume":"17","author":"Attarbaschi","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e31828b28d5","article-title":"Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response","volume":"33","author":"Bishara","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"111007","DOI":"10.1016\/j.pscychresns.2019.111007","article-title":"In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET","volume":"295","author":"Radhakrishnan","year":"2020","journal-title":"Psychiatry Res Neuroimaging"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02244926","article-title":"Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride","volume":"112","author":"Bench","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02245614","article-title":"The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography","volume":"124","author":"Bench","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(25)21208-3","article-title":"Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone","volume":"279","author":"Fischman","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck Jr","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00213-013-3012-1","article-title":"Dopamine D2\/3 occupancy of ziprasidone across a day: a within-subject PET study","volume":"228","author":"Suzuki","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF02245616","article-title":"In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia","volume":"124","author":"Martinot","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004714-200104000-00013","article-title":"In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia","volume":"21","author":"Xiberas","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145704004353","article-title":"High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia","volume":"7","author":"Vernaleken","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients","volume":"160","author":"Bressan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1076727","article-title":"Striatal D2\/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study","volume":"41","author":"Meisenzahl","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/schbul\/sbu220","article-title":"Striatal D(2\/3) binding potential values in drug-na\u00efve first-episode schizophrenia patients correlate with treatment outcome","volume":"41","author":"Wulff","year":"2015","journal-title":"Schizophrenia Bull"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","article-title":"Amisulpride\u2014dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring","volume":"120","author":"Sparshatt","year":"2009","journal-title":"Acta Psychiatrica Scand"},{"key":"R59-20250603","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"suppl B","key":"R60-20250603","first-page":"117","article-title":"Plasma clozapine concentrations as a predictor of clinical response: a follow-up study","volume":"55","author":"Miller","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"AM J Psychiatry"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.npp.1300931","article-title":"The striatal and extrastriatal D2\/D3 receptor-binding profile of clozapine in patients with schizophrenia","volume":"31","author":"Gr\u00fcnder","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1301108","article-title":"Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine","volume":"31","author":"Kessler","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pnpbp.2005.06.011","article-title":"Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations","volume":"30","author":"Takano","year":"2006","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(05)63079-6","article-title":"Limbic selectivity of clozapine","volume":"350","author":"Pilowsky","year":"1997","journal-title":"Lancet"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002130050492","article-title":"Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia","volume":"135","author":"Gefvert","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0924-977X(00)00133-4","article-title":"D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study","volume":"11","author":"Gefvert","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0925-4927(98)00020-1","article-title":"N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic","volume":"82","author":"Hagberg","year":"1998","journal-title":"Psychiatry Res Neuroimaging"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1017\/S1461145710000374","article-title":"Dopamine D2\/3 receptor occupancy by quetiapine in striatal and extrastriatal areas","volume":"13","author":"Vernaleken","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4088\/JCP.v69n0111","article-title":"Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study","volume":"69","author":"Mamo","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1017\/S1461145711000514","article-title":"Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects","volume":"14","author":"Nord","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","article-title":"Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine","volume":"213","author":"Rasmussen","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1017\/S1461145713000680","article-title":"Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR","volume":"16","author":"Nyberg","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ijnp\/pyx066","article-title":"A positron emission tomography study of norepinephrine transporter occupancy and its correlation with symptom response in depressed patients treated with quetiapine XR","volume":"21","author":"Yatham","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1017\/S1461145714000777","article-title":"Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients","volume":"17","author":"Rasmussen","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Gr\u00fcnder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D-2 and D-3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and C-11 raclopride (vol 27, pg 248, 2002)","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/npp.2008.33","article-title":"Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride","volume":"33","author":"Kegeles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study","volume":"165","author":"Gr\u00fcnder","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.09r05060gre","article-title":"A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring","volume":"71","author":"Sparshatt","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1007\/s00213-022-06233-2","article-title":"Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis","volume":"239","author":"Hart","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/jcbfm.2011.180","article-title":"Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship","volume":"32","author":"Kim","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00213-011-2633-5","article-title":"Striatal and extrastriatal dopamine D\u2082 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457","volume":"222","author":"Takahata","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00213-011-2633-5","article-title":"Striatal and extrastriatal dopamine D\u2082 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with raclopride and FLB457","volume":"222","author":"Takahata","year":"2012","journal-title":"Psychopharmacology"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41398-018-0134-6","article-title":"The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [(11)C]-raclopride PET study with aripiprazole","volume":"8","author":"Shin","year":"2018","journal-title":"Transl Psychiatry"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1038\/s41598-022-16130-5","article-title":"Relationship between subjective well-being and aripiprazole: an [(11)C]raclopride PET study","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-012-2953-0","article-title":"The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: a dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole","volume":"227","author":"Kim","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet Med"},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14737175.2013.853448","article-title":"Cariprazine, a new, orally active dopamine D2\/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression","volume":"13","author":"Veselinovi\u0107","year":"2013","journal-title":"Expert Rev Neurotherapeutics"},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [11C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.05.010","article-title":"Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data","volume":"45","author":"Tsuboi","year":"2013","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1176\/ajp.146.7.905","article-title":"Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia","volume":"146","author":"Wolkin","year":"1989","journal-title":"Am J Psychiatry"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2015.06.027","article-title":"Antipsychotic binding to the dopamine-3 receptor in humans: a PET study with [(11)C]-(+)-PHNO","volume":"168","author":"Girgis","year":"2015","journal-title":"Schizophrenia Res"},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/npp.2010.228","article-title":"In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO","volume":"36","author":"Girgis","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","article-title":"Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e31827b97a6","article-title":"Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia","volume":"33","author":"Lerond","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0269881110388329","article-title":"Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone","volume":"25","author":"Frankle","year":"2011","journal-title":"J Psychopharmacol"},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00213-015-4002-2","article-title":"Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers","volume":"232","author":"Sato","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpsychires.2016.12.023","article-title":"Representativeness of clinical PET study participants with schizophrenia: a systematic review","volume":"88","author":"Kirino","year":"2017","journal-title":"J Psychiatr Res"},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.4088\/JCP.13m08841","article-title":"Dose reduction of risperidone and olanzapine and estimated dopamine D\u2082 receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study","volume":"75","author":"Takeuchi","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophrenia Bull"},{"key":"R110-20250603","first-page":"212","article-title":"Dopamine D2\/3 receptor occupancy following dose reduction is predictable with minimal plasma antipsychotic concentrations: an open-label clinical trial","volume":"42","author":"Nakajima","year":"2016","journal-title":"Schizophr Bull"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:09:35Z","timestamp":1748970575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001131","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2023-04-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}